February 11, 2025 8:02am

Tariffs may only be seen with future inflation data while econs disrupt

Pre-open Indications: 1 Sell into Strength, 1 Positive and 4 Negative

Earnings: Sage Therapeutics (SAGE)

I am NOT often wrong and always consider doubt of some market and sector share pricing movements

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Monday’s night’s … RegMed Investors (RMi) Closing Bell: more of the downdraft as earnings will further their draft … https://www.regmedinvestors.com/articles/13798

 

Tuesday; the pre-open Dow futures are DOWN -0.17% or (-77 points), the S&P futures DOWN -0.25% or (-15 points) and the Nasdaq futures are DOWN -0.42% or (-92 points)

  • U.S. stock futures traded lower Tuesday as investors looked ahead to testimony from Fed Chair Powell,
  • European markets were trading flat,
  • Asia-Pacific markets traded mixed.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

During Monday’s main trading session, the Dow closed UP +167.01 points or +0.38%, the S&P closed UP +40.45 points or +0.67% while the Nasdaq closed UP +190.87 points or +0.98%

Economic Data Docket: Fed Chair Powell will speak before Congress …

  • CPI numbers on Wednesday and PPI on Thursday expected to show year-on-year declines in both the headline and the core readings

 

Q1/25: February – 4 negative and 2 positive closes

  • January – 2 holidays, 1 market close, 10 negative and 10 positive closes

Q4/24:

  • December 1 holiday, 15 negative and 5 positive closes
  • November 10 negative and 9 positive closes
  • October: 8 positive and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength:

Compass therapeutics (CMPX) closed up +$0.40 with a positive +$0.09 or +2.307% aftermarket

 

Negative:

Beam therapeutics (BEAM) closed down -$0.84 after Friday’s -$0.24 with a negative -0.11 or -0.11% pre-open

Blueprint Medicine (BPMC) closed down -$0.98 after Friday’s -$4.64 with a negative -$0.85 or -0.82% after market

CRISPR Therapeutics (CRSP) closed down -$0.30 with a negative -$0.24 or -0.61% pre-open

AxoGen (AXGN) closed down -$0.24 after Friday’s -$0.37 with a negative -$0.22 or -1.24% pre-open

 

Positive:

Ultragenyx Pharmaceuticals (RARE) closed down -$0.57 after Friday’s-$0.43 with a positive +$0.02 or +0.04% pre-open

 

The BOTTOM LINE: Merger and acquisition (M&A) activity, as sector companies will seek opportunities to sell to better financed companies that can "deal with these additional costs associated of R&D and escalating SG&A.

Prepare for earnings and more market volatility related to inflation oriented econs …

February ‘25: understand the “flow” …

  • 2/10 – Monday ended with a negative close at the close of 11 incliner, 23 decliners and 2 flats
  • 2/7 – Friday ended with a negative close at the close of 2 incliner, 31 decliners and 2 flats
  • 2/6 – Thursday ended with a negative close at the close of 8 incliner, 24 decliners and 3 flats
  • 2/5 - Wednesday ended with a positive close at the close of 26 incliner, 4 decliners and 5 flats
  • 2/4 - Tuesday ended with a positive close at the close of 24 incliner, 9 decliners and 2 flats
  • 2/3 – Monday - ended with a negative close at the close of 8 incliner, 25 decliners and 2 flats

 

Earnings are a-comin’ … from Q4/24 and FY24 are due …

  • Sage Therapeutics (SAGE) - Today
  • Blueprint Medicine (BPMC) – Thursday, 2/13
  • Alnylam Pharmaceuticals (ALNY), Thursday, 2/13
  • Ultragenyx Pharmaceuticals (RARE). Thursday, 2/13
  • Moderna (MRNA) - Friday, 2/14
  • Ionis pharmaceuticals IONS) – Wednesday, 2/19
  • MiMedx (MDXG) – Wednesday, 2/26

 

What could 2025 have in store for the capital access space as Partners are the gift of life!

  • "You'll see a number of cell and gene therapy comandantes drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in the market… capital expansion is second.

I seem to be asking a question followed by a question …

  • Do we need to brace ourself for more economics and their down trending affect?
  • Is this market STILL “bubblicious” my concerns are macroeconomic and valuation

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.